methyl (4R,5R)-2,2-dimethyl-5-(2-thiophen-2-ylethylcarbamoyl)-1,3-dioxolane-4-carboxylate | 871724-22-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl (4R,5R)-2,2-dimethyl-5-(2-thiophen-2-ylethylcarbamoyl)-1,3-dioxolane-4-carboxylate
• CAS: 871724-22-0
• 化学式: C₁₄H₁₉NO₅S
• 分子量: 313.375
• InChiKey: ADCHZGUCHWUPRE-GHMZBOCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl (4R,5R)-2,2-dimethyl-5-(2-thiophen-2-ylethylcarbamoyl)-1,3-dioxolane-4-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以53%的产率得到(4R,5R)-2,2-dimethyl-5-(2-thiophen-2-ylethylcarbamoyl)-1,3-dioxolane-4-carboxylic acid
  参考文献：
  名称：

  The discovery of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors

  摘要：

  A novel series of TNF-alpha convertase (TACE) inhibitors which are non-hydroxamate have been discovered. These compounds are bis-amides of L-tartaric acid (tartrate) and coordinate to the active site zinc in a tridentate manner. They are selective for TACE over other MMP's. We report the first X-ray crystal structure for a tartrate-based TACE inhibitor. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.004
• 作为产物：
  描述：

  噻吩乙胺 、 (4R,5R)-5-(methoxycarbonyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以64%的产率得到methyl (4R,5R)-2,2-dimethyl-5-(2-thiophen-2-ylethylcarbamoyl)-1,3-dioxolane-4-carboxylate
  参考文献：
  名称：

  The discovery of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors

  摘要：

  A novel series of TNF-alpha convertase (TACE) inhibitors which are non-hydroxamate have been discovered. These compounds are bis-amides of L-tartaric acid (tartrate) and coordinate to the active site zinc in a tridentate manner. They are selective for TACE over other MMP's. We report the first X-ray crystal structure for a tartrate-based TACE inhibitor. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.004

文献信息

• Compounds for the treatment of inflammatory disorders
  申请人：Siddiqui Arshad M.

  公开号：US20060178366A1

  公开（公告）日：2006-08-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式（I）的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• Compounds for the treatment of inflammatory disorders and microbial diseases
  申请人：Siddiqui Arshad M.

  公开号：US20070167426A1

  公开（公告）日：2007-07-19

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式(I)的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Guo Zhuyan

  公开号：US20100145048A1

  公开（公告）日：2010-06-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及公式(I)的化合物：或其药学上可接受的盐、溶剂化合物或异构体，可用于治疗由MMPs、ADAMs、TACE、TNF-α或其组合介导的疾病或病症。
• [EN] CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：SCHERING CORP

  公开号：WO2005121130A3

  公开（公告）日：2006-07-20
• US7638513B2
  申请人：——

  公开号：US7638513B2

  公开（公告）日：2009-12-29